(Arg)9 acetate (Synonyms: Nona-L-arginine acetate; Peptide R9 acetate) |
| カタログ番号GC66389 |
(Arg)9 (ノナ-L-アルギニン) アセテートは、9 つのアルギニン残基で構成される細胞透過性ペプチド (CPP) です。 (Arg)9 アセテートには神経保護特性があり、グルタミン酸モデルで 0.78 μM の IC50 で神経保護活性を示します。
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 0.78 μM (neuroprotection)[1]
(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model[1][2].
(Arg)9 (Nona-L-arginine; 5-10 μM) acetate provides significant neuroprotection in a dose-response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 acetate is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 acetate also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
(Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); i.v.; once, for 30min; male Sprague-Dawley ratspermanent middle cerebral artery stroke model) acetate shows neuroprotective effects and reduces infarct volume[2].
| Animal Model: | Male Sprague-Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model[2] |
| Dosage: | 1 μM/kg (600 μL) |
| Administration: | Intravenous injection; once, over 5 minutes |
| Result: | Reduced significantiy 20% in infarct volume. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *